Related Experiment Video

Updated: Jul 7, 2025

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

2.6K

Epigenetic targeting of autophagy for cancer: DNA and RNA methylation

Luobin Lin1, Yuntao Zhao1, Qinzhou Zheng1

  • 1Guangdong Province Key Laboratory of Biotechnology Drug Candidates, School of Life Sciences and Biopharmaceuticals, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.

Frontiers in Oncology
|December 27, 2023
PubMed

Insights

Epigenetic modifications, including DNA N6-methyldeoxyadenosine (6mA) and RNA N6-methyladenosine (m6A), significantly regulate autophagy. Understanding these methylation marks offers novel therapeutic strategies for cancer by modulating autophagy.

Area of Science:

  • Cellular Biology
  • Epigenetics
  • Molecular Oncology

Background:

  • Autophagy is a vital cellular process for degradation and recycling, with complex roles in cancer, acting as both a tumor suppressor and promoter.
  • Epigenetic modifications, specifically DNA 6mA and RNA m6A, are emerging as key regulators of cellular processes, including autophagy.
  • The interplay between these methylation marks and autophagy is critical for understanding cancer development and progression.

Purpose of the Study:

  • To review the current understanding of DNA 6mA and RNA m6A methylation in the context of autophagy regulation.
  • To explore the influence of these epigenetic modifications on autophagy pathways in cancer.
  • To highlight the potential of targeting 6mA, m6A, and autophagy for novel cancer therapies.

Main Methods:

  • Literature review of studies investigating DNA 6mA, RNA m6A, and autophagy in cancer.
  • Analysis of the molecular mechanisms linking epigenetic modifications to autophagic activity.
  • Synthesis of current research on the therapeutic implications of targeting these pathways.

Main Results:

  • DNA 6mA and RNA m6A modifications are integral to the intricate network regulating autophagy.
  • These epigenetic marks influence the expression and function of genes involved in autophagic pathways, impacting cancer biology.
  • Dysregulation of 6mA and m6A is associated with altered autophagic flux in various cancers.

Conclusions:

  • DNA 6mA and RNA m6A represent crucial epigenetic layers controlling autophagy.
  • Targeting these methylation modifications offers promising therapeutic avenues for cancer intervention by modulating autophagy.
  • Further research into the 6mA-m6A-autophagy axis is warranted for developing innovative cancer treatments.
Keywords:
6mA methylationautophagycancersm6A methylationtherapy

More Related Videos

Methylated DNA Immunoprecipitation21:24

Methylated DNA Immunoprecipitation

Published on: January 2, 2009

23.4K
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

5.6K

Related Concept Videos

Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
4.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Delivery Pathways to the Lysosome01:36

Delivery Pathways to the Lysosome

Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
6.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K